Holen Sie sich die Stockscreener-App
25.58
0.22%
-16.44
Schlusskurs vom Vortag:
$9.14
Offen:
$25.51
24-Stunden-Volumen:
3,813
Relative Volume:
466.03
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-13.61
EPS:
-1.88
Netto-Cashflow:
-
1W Leistung:
+0.00%
1M Leistung:
-2.04%
6M Leistung:
+10.95%
1J Leistung:
-15.87%
1-Tages-Spanne:
$25.51
$25.58
1-Wochen-Bereich:
$25.51
$25.58
52-Wochen-Spanne:
$25.51
$25.58
Flexion Therapeutics, Inc. Stock (FLXN) Company Profile
Firmenname
Flexion Therapeutics, Inc.
Sektor
Telefon
781-305-7777
Adresse
10 Mall Road, Suite 301, Burlington
Vergleichen Sie FLXN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FLXN
Flexion Therapeutics, Inc.
|
25.55 | 0 | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
123.76 | 55.23B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.93 | 51.37B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.805 | 43.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.64 | 37.62B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
476.24 | 20.77B | 3.08B | 1.24B | 1.07B | 25.61 |
Flexion Therapeutics, Inc. Stock (FLXN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-08-20 | Eingeleitet | Goldman | Neutral |
| 2020-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2020-07-29 | Eingeleitet | Credit Suisse | Outperform |
| 2020-06-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-27 | Eingeleitet | Guggenheim | Buy |
| 2019-12-27 | Bestätigt | The Benchmark Company | Buy |
| 2019-12-05 | Eingeleitet | Craig Hallum | Buy |
| 2019-11-25 | Eingeleitet | BTIG Research | Buy |
| 2019-05-09 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2019-01-04 | Bestätigt | Needham | Buy |
| 2019-01-04 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2018-06-28 | Eingeleitet | The Benchmark Company | Buy |
| 2017-10-09 | Bestätigt | Needham | Buy |
| 2017-08-24 | Eingeleitet | Northland Capital | Outperform |
| 2016-12-22 | Eingeleitet | Raymond James | Strong Buy |
| 2016-09-06 | Fortgesetzt | Lake Street | Buy |
| 2016-07-21 | Eingeleitet | Lake Street | Buy |
| 2016-05-03 | Fortgesetzt | Wells Fargo | Outperform |
| 2015-11-04 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-09-09 | Bestätigt | Needham | Buy |
Alle ansehen
Flexion Therapeutics, Inc. Aktie (FLXN) Neueste Nachrichten
Flexion Therapeutics, Inc.Common Stock (NQ: FLXN - FinancialContent
Flexion Therapeutics Announces Publication of Analysis of Patients with Unilateral Knee OA from Pivotal Trial of ZILRETTA® (... - ADVFN
Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates - ADVFN
Flexion Therapeutics Announces Publication of Independent Data Review of ZILRETTA® (triamcinolone acetonide extended-release... - ADVFN
Flexion Therapeutics Announces Publication of Pooled Analysis of Phase 2/3 Data on Use of Rescue Medication with ZILRETTA® (... - ADVFN
Osteoarthritis Therapeutics Market Size to Hit USD 26.31 billion by 2035 - Precedence Research
Anti-Inflammatory Therapeutics Market Size to Hit USD 164.44 Bn by 2035 - Precedence Research
Knee Osteoarthritis Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - The Globe and Mail
Musculoskeletal Pain Treatment Market Size (7MM) is expected to grow at a significant CAGR by 2034, estimates DelveInsight - The Globe and Mail
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer - pharmiweb.com
Musculoskeletal Pain Treatment Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight - openPR.com
Osteoarthritis Gene Therapy Market Research Report 2025 - InsightAce Analytic
Knee Osteoarthritis Pipeline Drugs Insights Report 2025: Emerging Therapeutics and Market Opportunities Revealed | DelveInsight - The Globe and Mail
Knee Osteoarthritis Pipeline Drugs Insights Report 2025: - openPR.com
Swollen Knee Treatment Market Expands as Demand for Non-Invasive Therapies Accelerates Globally - newstrail.com
Cipher Mining Inc.Common Stock (NQ: CIFR - FinancialContent
Knee osteoarthritis Market: Epidemiology, Therapies, Companies, DelveInsight | Centrexion Therapeutics, Pfizer, Eli Lilly, Ampio Pharmaceuticals, Galapagos NV, Cytonics, Flexion Therapeutics - Barchart.com
Knee Osteoarthritis Pipeline Analysis 2025: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight - The Globe and Mail
Postoperative Pain Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight - openPR.com
Non-opioid pain drug maker Pacira lays off 71 in California, retires facility in manufacturing upgrade - Fierce Pharma
Postoperative Pain Pipeline 2025: FDA Updates, Therapy Innovations, And Clinical Trial Landscape Analysis By Delveinsight Allay Therapeutics, Siteone Therapeutics, Lipocure, Flexion Therapeutics - MenaFN
T-knife Therapeutics Appoints Christoph Broja to its Board of Directors - GlobeNewswire
Non-Opioid Pain Treatment Market Size, Share | CAGR Of 8.1% - Market.us
High Costs of Knee Osteoarthritis Treatment - Market.us
Knee Osteoarthritis (OA) Injectable Treatments Market Revenue to Attain USD 5.94 Bn by 2033 - Precedence Research
Osteoarthritis Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2025-2034) | DelveInsight - The Malaysian Reserve
Syncromune Appoints Kerri-Ann Millar as Chief Financial Officer - citybiz
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer - GlobeNewswire
Marquis Who's Who Honors Shomari Hogan, MD, for Expertise in Consulting Services - 24-7 Press Release Newswire
Osteoarthritis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Revenue, Statistics, Therapies, and Companies by DelveInsight - Barchart.com
Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewswire
CPRXCatalyst Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan
Flexion nabs FDA OK for its potential blockbuster osteoarthritis drug, triggering new buyout buzz - Endpoints News
Osteoarthritis Therapeutics Market Size to Reach USD 24.34 Bn by 2034 - GlobeNewswire
From bench to bedside: Osteoarthritis gene therapy developed in the lab at Baylor is in clinical trials nationwide - Baylor College of Medicine Blog Network -
Gene Therapies For Rare Diseases Market Share, Size, Growth and Forecast to 2031 - Insightace Analytic
Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth - Yahoo Finance
Pacira BioSciences Reports Third Quarter 2024 Financial Results - GlobeNewswire
Global Anti-Aging Products Market is Projected to Cross ~USD 112 Billion by 2030 | DelveInsight - GlobeNewswire
U.S. Osteoarthritis Injectables Market Analysis 2024-2030: - GlobeNewswire
Anti-Inflammatory Therapeutics Market Business Strategy, Top Manufactures And Forecast 2031 - newstrail.com
Global Non-Steroidal Anti-Inflammatory Drugs Market is - GlobeNewswire
Avalo Therapeutics Welcomes Chief Medical Officer - Contract Pharma
Madison Topic FLEXION THERAPEUTICS, INC. | News, Weather, Sports, Breaking News - WMSN
Osteoarthritis Injectables Market Size & Share Report, 2030 - Grand View Research
U.S. Osteoarthritis Injectables Market | Industry Report, 2030 - Grand View Research
Global Medical Dynamometers Market to Witness Upsurge in Growth at a CAGR of ~6% by 2030 | DelveInsight - PR Newswire
Osteoarthritis Therapeutics Market Size & Share Report 2030 - Grand View Research
Ocular Therapeutix Appoints Steve Meyers as Chief Commercial Officer - citybiz
Adipo Therapeutics completes $1.9M seed funding bridge to advance obesity and Type 2 diabetes treatment - Purdue University
Postoperative Pain Market is Projected to Grow at a CAGR of 7.2% by 2032 | DelveInsight - GlobeNewswire
Finanzdaten der Flexion Therapeutics, Inc.-Aktie (FLXN)
Es liegen keine Finanzdaten für Flexion Therapeutics, Inc. (FLXN) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
2.08%
0.67%
Kapitalisierung:
|
Volumen (24h):